NCT06664151View on ClinicalTrials.gov

A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 26, 2024

Primary Completion Date

August 30, 2026

Study Completion Date

August 30, 2026

Conditions
Skin CancerCutaneous Squamous Cell Carcinoma (CSCC)Cutaneous Squamous Cell Cancer
Interventions
BIOLOGICAL

Fluzone Trivalent

Inactivated influenza vaccine, 0.5mL single-dose, pre-filled syringe, via intratumoral (into a tumor) injection per protocol.

Trial Locations (2)

02215

RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER